Terms of Use

1. Acceptance of Terms

These Terms of Use govern access to and use of AXIONOVA^™ websites, applications, professional portals, governed access gates, compounding documentation, compound formularies, device-related workflows, data-room materials, AI-assisted support, and related services. By accessing or using any AXIONOVA^™ service, submitting an access request, signing an electronic acknowledgement, entering a Datasite data room, using AXIONOVA^™ bio, interacting with ALETHA^™, or accepting DocuSign documents, you agree to these Terms.

If you access AXIONOVA^™ on behalf of a clinic, longevity center, reseller, research entity, professional corporation, or other organization, you represent that you have authority to bind that organization and that the organization will comply with these Terms. If you do not agree, you must not access restricted AXIONOVA^™ materials.

2. AXIONOVA^™ Platform Roles

AXIONOVA^™ operates a governed precision bio-science and longevity platform. The platform uses defined roles and system boundaries so users understand what each layer does and does not do.

3. Eligibility and Two-Path Governed Access

AXIONOVA^™ restricted materials are available only through governed access pathways. Path 1 may include licensed practitioners, clinics, medical institutes, qualified research entities, authorized resellers, and approved business partners that submit required credentials and documentation. Path 2 may include trainers, spas, coaches, and individual applicants who are routed through AXIONOVA^™’s on-staff doctors for telehealth oversight. AXIONOVA^™ does not provide unmanaged access, unsupervised self-administration, resale channels, therapeutic claims, or emergency-service guarantees. AXIONOVA^™ may deny, suspend, revoke, or condition access where required for prescription-requirement compliance, professional standards, privacy, security, diversion risk, jurisdictional requirements, or legal risk.

You must be at least 21 years old or the legal age required in your jurisdiction, whichever is higher, and must have legal authority to access the relevant service. You must provide accurate, current, and complete information during access screening, credential review, partner onboarding, DocuSign workflows, data-room access, and account registration. AXIONOVA^™ may deny, suspend, revoke, or condition access if it determines that information is inaccurate, credentials are insufficient, intended use is inconsistent with prescription-based access restrictions, or access could create regulatory, safety, diversion, security, reputational, or legal risk.

4. Prescription Required; No Over-the-Counter or Consumer Sale

All compounds referenced on this platform are compounded medications that require a valid prescription. They are not offered as FDA-approved drugs, over-the-counter products, dietary supplements, or medical advice. Access requires physician authorization. AXIONOVA^™ compounds, compound documentation, protocol structures, stack logic, formulation records, and formulary materials are not offered or intended as diagnoses, treatments, cures, disease-prevention claims, or substitutes for licensed clinical judgment; all clinical decisions are made by licensed physicians.

Compounded medications are prepared by licensed pharmacies for individually identified patients pursuant to valid prescriptions issued by licensed healthcare providers. Compounded medications are not FDA-approved, and the FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. This does not mean every AXIONOVA^™ compound, device, or workflow shares a single legal classification; final product classification must be confirmed by counsel and regulatory advisors.

You must not represent AXIONOVA^™ materials as FDA-approved products unless AXIONOVA^™ has provided written authorization supported by the required regulatory clearances, registrations, approvals, or professional frameworks. You must not make unauthorized claims that any AXIONOVA^™ compound, system, protocol, device, AI output, or platform record diagnoses, treats, mitigates, cures, or prevents disease.

5. Professional, Clinic, Research Entity, and Reseller Obligations

If you are a practitioner, clinic, longevity center, reseller, research entity, or professional operator, you are responsible for complying with all laws, regulations, professional standards, institutional policies, ethical rules, licensing restrictions, import/export requirements, storage requirements, advertising requirements, consumer-protection rules, privacy obligations, and informed-consent obligations applicable to your role and jurisdiction.

AXIONOVA^™ may require additional written agreements, business associate agreements, reseller agreements, clinical-access agreements, platform-use acknowledgements, quality documents, certificates, chain-of-custody records, and DocuSign attestations before granting or maintaining access.

6. No Medical Relationship; No Emergency Use

AXIONOVA^™ does not create a physician-patient, provider-patient, pharmacist-patient, or therapeutic relationship merely by providing website content, access-gate forms, compounding documentation, AXIONOVA^™ bio records, ALETHA^™ coaching, AXIONOVA^™ Ring and Bracelet trends, AXIS event data, or practitioner-facing tools. ALETHA^™ and AXIONOVA^™content are not emergency services. If an individual may be experiencing a medical emergency, that individual must contact emergency services or a licensed medical professional immediately.

AXIONOVA^™ AGIS Preventative Monitoring and Safety Escalation Workflow Boundary

AXIONOVA^™ AGIS is designed first for preventative biometric monitoring, baseline-aware optimization, signal-confidence review, and governed context preparation. Safety Escalation Workflow is an exclusive AXIONOVA^™ AGIS capability only where configured, validated for the applicable workflow, consented, jurisdictionally available, legally supported, and approved through AXIONOVA^™’s governed access process. AXIONOVA^™ AGIS is a biometric monitoring tool; its readings do not constitute a medical diagnosis, and all clinical interpretation and treatment decisions are made exclusively by licensed physicians. It does not guarantee detection of every emergency and does not replace direct contact with emergency services or licensed medical professionals. Users remain responsible for contacting emergency services directly when they believe emergency assistance is needed.

7. AI-Assisted Outputs and Practitioner Review

ALETHA^™ may generate explanations, summaries, educational content, adherence prompts, progress summaries, support responses, preparatory questions, or practitioner-review flags. ALETHA^™ outputs may be incomplete, incorrect, stale, or unsuitable for a user’s context. Users and professional operators must independently evaluate any output before relying on it.

AXIONOVA^™ may label outputs as measured, derived, specialized, wellness, prescription-governed, confidence-limited, or practitioner-review-required. Users must not remove, obscure, or contradict these boundary labels. Protocol-dependent decisions must be routed through the appropriate authorized practitioner, clinic, research entity, or governance process.

8. Accounts, Credentials, and Security

You are responsible for maintaining the confidentiality of account credentials, DocuSign links, Datasite invitations, API keys if any, device pairings, and portal access. You must promptly notify AXIONOVA^™ of suspected unauthorized access, credential compromise, device theft, data-room misuse, diversion risk, or breach of these Terms.

You may not share accounts, impersonate another person, bypass access controls, scrape restricted catalog content, reverse engineer protected systems, interfere with security, test vulnerabilities without written authorization, or use AXIONOVA^™ systems to transmit malware, unlawful content, misleading claims, or unauthorized health-related instructions.

9. Audit Trails, Monitoring, and Access Revocation

AXIONOVA^™ may monitor, log, and audit access to restricted materials, AXIONOVA^™ bio, ALETHRA^™ records, Datasite rooms, DocuSign workflows, partner portals, and access-gate activity. Logs may include user identity, IP address, timestamp, device, documents viewed, signatures, acknowledgements, downloads, data exports, cartridge or device events, and compliance actions.

AXIONOVA^™ may suspend, revoke, restrict, or condition access at any time if it identifies suspected misuse, diversion risk, unauthorized claims, credential issues, privacy or security concerns, noncompliance with prescription-based access restrictions, regulatory risk, breach of confidentiality, or breach of these Terms.

10. Reservations, Availability, and Pre-Order Communications

AXIONOVA^™ may allow no-cost reservations or interest-list submissions for AXIS, AXIONOVA^™ Ring, AXIONOVA^™ Bracelet, or other products. A reservation does not require payment, does not guarantee product availability, does not create a purchase right, does not guarantee launch timing, does not establish regulatory eligibility, and does not override any clinical, professional, jurisdictional, or access restrictions.

AXIONOVA^™ may contact reservation holders with product updates, availability windows, onboarding steps, professional eligibility requirements, and access instructions. Final product availability, features, specifications, pricing, compliance requirements, and jurisdictions may change.

11. Orders, Payments, Shipping, Import, and Export

Unless AXIONOVA^™ provides a separate written agreement, purchase order, reseller agreement, clinical-access agreement, invoice, or supply agreement, access to AXIONOVA^™ materials does not constitute a sale, offer to sell, prescription, dispensing instruction, import authorization, export authorization, or regulatory approval.

Any orders, shipments, imports, exports, customs entries, logistics, storage, handling, labeling, and distribution involving AXIONOVA^™ materials must comply with applicable U.S., Mexico, and other jurisdictional requirements. The Mexican health-regulatory authority COFEPRIS oversees health inputs, health establishments, sanitary permits, sanitary registrations, licenses, import and related proceedings in Mexico. AXIONOVA^™ may require confirmation of required permits, registrations, licenses, import authorizations, and professional permissions before allowing any transaction.

12. Advertising, Marketing, and Claim Restrictions

All statements about AXIONOVA^™, AXIONOVA^™ compounds, biological systems, protocol structures, stacks, AXIS, the AXIONOVA^™ Ring and Bracelet, AXIONOVA^™ bio, ALETHA^™, ALETHRA^™, or platform outputs must be truthful, non-misleading, appropriately substantiated, and consistent with AXIONOVA^™-approved materials. FTC health-products guidance requires that health-related claims be truthful, not misleading, and supported by adequate substantiation, typically competent and reliable scientific evidence.

Mexico’s Federal Consumer Protection Law requires information and advertising to be truthful, verifiable, clear, and free from misleading or abusive content, and Article 76 Bis imposes obligations for electronic transactions, including confidentiality, security, truthful product characteristics, clear terms, and respect for consumer advertising preferences.

You must not make unauthorized testimonials, before-and-after claims, disease claims, efficacy claims, safety claims, comparative claims, “guaranteed result” claims, “approved” claims, or unauthorized use claims. You must not market compounded medications to consumers as over-the-counter products; they may be dispensed only pursuant to valid prescriptions. You must not imply that AXIONOVA^™has endorsed your marketing unless AXIONOVA^™ has provided written approval.

13. Electronic Communications and CAN-SPAM

By providing contact information, you agree that AXIONOVA^™ may send service, security, compliance, access-gate, data-room, DocuSign, reservation, onboarding, professional, and marketing communications. Commercial email communications will be managed to comply with CAN-SPAM requirements, including accurate sender information, non-deceptive subject lines, required advertising identification where applicable, physical address disclosure, opt-out mechanisms, honoring opt-outs within 10 business days, and monitoring vendors sending on AXIONOVA^™’s behalf.

You may opt out of marketing emails, but AXIONOVA^™ may continue to send transactional or relationship communications necessary for account administration, restricted access, security, compliance, electronic signatures, legal notices, practitioner review, and platform operation.

14. Electronic Signatures, Electronic Records, and DocuSign

AXIONOVA^™ may use DocuSign or similar electronic-signature tools for agreements, consents, acknowledgements, prescription-access attestations, access authorizations, reseller terms, data-room obligations, and compliance records. Under the U.S. ESIGN Act, a signature, contract, or record relating to interstate or foreign commerce may not be denied legal effect solely because it is electronic, and a contract may not be denied enforceability solely because an electronic signature or record was used.

By using DocuSign or accepting electronic records, you consent to transact electronically with AXIONOVA^™for the applicable transaction and agree that your electronic signature, click acceptance, checkbox acknowledgement, access-gate attestation, or similar electronic action is intended to authenticate and bind you. Where legally required, AXIONOVA^™ will provide consumer e-record disclosures regarding paper-copy rights, withdrawal of consent, categories of records, and hardware/software requirements.

15. Privacy and Data Protection

AXIONOVA^™’s collection, use, disclosure, retention, and protection of personal information are governed by the AXIONOVA^™ Privacy Policy. In Mexico, the LFPDPPP requires a privacy notice identifying the controller, personal data categories, purposes, transfer terms, ARCO rights mechanisms, and procedures for notice changes. In the United States, state privacy laws may provide rights to know, delete, correct, opt out, limit sensitive data uses, and avoid discrimination, depending on applicability.

Professional operators must obtain all legally required consents and authorizations before submitting personal information, health-related data, laboratory results, biometric data, device records, images, notes, or practitioner annotations to AXIONOVA^™.

16. Confidentiality and Data Rooms

Datasite rooms, diligence materials, certificates, lot records, compound documentation, technical specifications, device architecture, partner terms, pricing, research logic, source documents, and non-public AXIONOVA^™ materials are confidential unless AXIONOVA^™ expressly designates them as public. You must not copy, download, disclose, photograph, scrape, summarize for public release, train models on, or distribute confidential materials except as authorized in writing.

AXIONOVA^™ may watermark, log, restrict, revoke, or audit data-room access. Confidentiality obligations survive termination of access.

17. Intellectual Property

AXIONOVA^™ and its licensors retain all rights in AXIONOVA^™ names, marks, logos, trade dress, designs, software, content, technical documentation, ALETHA^™/ALETHRA^™ logic, AXIONOVA^™ bio interfaces, AXIS and AXIONOVA^™ Ring and Bracelet specifications, catalogs, protocols, system taxonomies, compound records, templates, workflows, text, images, videos, and data structures. No license is granted except the limited, revocable, non-exclusive right to access authorized materials for permitted use under these Terms.

You must not use AXIONOVA^™ trademarks, screenshots, catalog content, compound documentation, device visuals, AI outputs, or technical materials in marketing, resale, fundraising, training, regulatory submissions, publications, or public communications without AXIONOVA^™’s written permission.

18. User Content and Submitted Materials

You may submit information, documents, notes, lab results, device data, questions, comments, feedback, intended-use statements, credentials, or other content to AXIONOVA^™. You represent that you have all rights, permissions, consents, and authority necessary to submit that content. You grant AXIONOVA^™ a limited right to process, store, use, display, reproduce, transmit, and create operational summaries of submitted content as necessary to provide the services, operate ALETHRA^™ governance, support ALETHA^™assistance, maintain records, comply with law, enforce these Terms, and improve controlled-access workflows.

You must not submit unlawful, misleading, defamatory, infringing, unsafe, unauthorized, or sensitive third-party information without proper authority.

19. Third-Party Services and Integrations

AXIONOVA^™ may use or link to third-party services such as Attio, Datasite, DocuSign, cloud providers, email providers, analytics tools, laboratories, wearable or CGM integrations, logistics providers, payment providers if implemented, and professional software. Third-party services may have their own terms, privacy notices, security practices, and availability limits. AXIONOVA^™ is not responsible for third-party systems outside AXIONOVA^™’s control, except as required by applicable law or written agreement.

20. Disclaimers of Warranties

To the maximum extent permitted by law, AXIONOVA^™ services, content, records, AI outputs, data-room materials, compounding documentation, websites, portals, reservation workflows, and integrations are provided on an “as is” and “as available” basis. AXIONOVA^™ disclaims all warranties, express, implied, statutory, or otherwise, including implied warranties of merchantability, fitness for a particular purpose, non-infringement, accuracy, availability, regulatory suitability, clinical suitability, research outcome, uninterrupted operation, and error-free performance.

AXIONOVA^™ does not warrant that any compound, device, system, protocol, AI output, wellness trend, practitioner annotation, platform record, or data-room document will achieve a particular result, qualify for a particular regulatory pathway, satisfy a user’s professional obligations, or be suitable for any particular patient.

21. Limitation of Liability

To the maximum extent permitted by law, AXIONOVA^™ and its affiliates, officers, directors, employees, contractors, licensors, service providers, and partners will not be liable for indirect, incidental, consequential, special, exemplary, punitive, lost-profit, lost-revenue, lost-data, reputational, business-interruption, regulatory, clinical, or research-outcome damages arising from or related to the services, even if advised of the possibility of such damages.

To the maximum extent permitted by law, AXIONOVA^™’s total liability arising out of or related to these Terms or the services will not exceed the greater of (a) amounts paid by you to AXIONOVA^™ for the specific service giving rise to the claim during the 12 months before the claim, or (b) [USD $100]. Some jurisdictions do not allow certain limitations, so these limits apply only to the extent permitted by law.

22. Indemnification

You agree to defend, indemnify, and hold harmless AXIONOVA^™ and its affiliates, officers, directors, employees, contractors, licensors, service providers, and partners from claims, losses, damages, liabilities, penalties, fines, costs, and expenses, including reasonable attorneys’ fees, arising from or related to your breach of these Terms, unauthorized claims or marketing, misuse of prescription-restricted materials, violation of law, privacy or consent failures, unauthorized resale or diversion, improper professional conduct, submitted content, security compromise caused by you, or use of AXIONOVA^™ materials outside authorized boundaries.

23. Suspension and Termination

AXIONOVA^™ may suspend or terminate access to any service, account, portal, data room, API, catalog, reservation list, DocuSign workflow, device integration, or communication channel at any time for violation of these Terms, suspected misuse, legal risk, security risk, nonpayment if applicable, inaccurate information, credential failure, unauthorized claims, diversion risk, or discontinuation of services.

Upon termination, you must stop using restricted materials and return or destroy confidential materials if requested, subject to legally required record retention. Sections concerning prescription-access restrictions, professional obligations, confidentiality, intellectual property, privacy, disclaimers, liability limits, indemnification, governing law, dispute resolution, and record retention survive termination.

24. Changes to Services and Terms

AXIONOVA^™ may modify, suspend, discontinue, or restrict any service, feature, product, catalog, protocol structure, device integration, AI function, data-room workflow, jurisdictional availability, or reservation program. AXIONOVA^™ may update these Terms by posting a revised version or providing notice where required. Continued use after an update constitutes acceptance unless applicable law requires affirmative consent.

25. Governing Law and Dispute Resolution

These Terms are governed by the laws of [Insert governing U.S. state], excluding conflict-of-law rules, except to the extent mandatory laws of Mexico, consumer-protection laws, data-protection laws, professional regulations, health regulations, or other non-waivable jurisdictional laws apply. Counsel should confirm whether AXIONOVA^™ will use court litigation, arbitration, venue selection, class-action waiver, jury-trial waiver, or bilingual dispute provisions.

Any dispute must first be escalated to AXIONOVA^™’s legal contact at legal@axionova.com for good-faith resolution. Nothing in these Terms limits a party’s right to seek injunctive relief for misuse of confidential information, intellectual property, restricted access materials, security systems, or compounding documentation.

26. Contact

Legal notices and Terms-related questions may be sent to: